bupropion has been researched along with buspirone in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (47.06) | 29.6817 |
| 2010's | 18 (52.94) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Johans, C; Kinnunen, PK; Söderlund, T; Suomalainen, P | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Boriss, H; Braggio, S; Corbioli, S; Fontana, S; Helmdach, L; Longhi, R; Schiller, J; Vinco, F | 1 |
| Chang, G; Di, L; Huang, Y; Lin, Z; Liston, TE; Scott, DO; Troutman, MD; Umland, JP | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Adams, DP; Covey, LS; Glassman, AH; Johnston, JA; Robinson, MD; Sullivan, MA | 1 |
| Zajecka, J | 1 |
| Detweiler, MB; Harpold, GJ | 1 |
| Chrousos, GP; Gabry, KE; Gold, PW; McCann, SM; Mostafa, RM; Negrao, AB; Rice, KC; Sternberg, E; Webster, EL | 1 |
| Biggs, MM; Fava, M; Lebowitz, BD; Luther, JF; Nierenberg, AA; Quitkin, F; Ritz, L; Rush, AJ; Shores-Wilson, K; Thase, ME; Trivedi, MH; Warden, D; Wisniewski, SR | 1 |
| Williams, SC | 1 |
| Taylor, MJ | 1 |
| Biggs, MM; Fava, M; Friedman, ES; Hollon, SD; Luther, JF; McGrath, PJ; Niederehe, G; Nierenberg, AA; Rush, AJ; Thase, ME; Trivedi, MH; Warden, D; Wisniewski, SR | 1 |
| Fava, M | 1 |
| Shelton, RC | 1 |
| Balasubramani, GK; Kornstein, SG; Lesser, IM; Nierenberg, AA; Preskorn, SH; Rush, AJ; Shores-Wilson, K; Thase, ME; Trivedi, MH; Warden, D; Wisniewski, SR; Young, EA | 1 |
| Nierenberg, AA | 1 |
| Laje, G; McMahon, FJ; Perlis, RH; Rush, AJ | 1 |
| Dusetzina, SB; Ellis, AR; Farley, JF; Gaynes, BN; Hansen, RA; Miller, WC; Stürmer, T | 2 |
| Bech, P; Fava, M; Rush, AJ; Trivedi, MH; Wisniewski, SR | 1 |
| Fava, M; Perlis, RH; Perroud, N; Uher, R | 1 |
| Bijlsma, EY; Chan, JS; Millan, MJ; Olivier, B; Oosting, RS; Veening, JG; Waldinger, MD | 1 |
| Bielefeldt, K; Szigethy, E; Thorkelson, G | 1 |
6 review(s) available for bupropion and buspirone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Advances in non-nicotine pharmacotherapy for smoking cessation.
Topics: Antidepressive Agents; Bupropion; Buspirone; Clonidine; Humans; Moclobemide; Narcotic Antagonists; Smoking Cessation | 2000 |
Strategies for the treatment of antidepressant-related sexual dysfunction.
Topics: Antidepressive Agents; Bupropion; Buspirone; Central Nervous System Stimulants; Depressive Disorder; Drug Administration Schedule; Female; Humans; Male; Patient Compliance; Piperazines; Purines; Quality of Life; Secondary Prevention; Serotonin Antagonists; Sexual Dysfunctions, Psychological; Sexuality; Sildenafil Citrate; Sulfones | 2001 |
Strategies for managing antidepressant-induced sexual dysfunction: a review.
Topics: Antidepressive Agents; Bupropion; Buspirone; Depressive Disorder; Erectile Dysfunction; Female; Ginkgo biloba; Granisetron; Humans; Male; Randomized Controlled Trials as Topic; Sexual Dysfunction, Physiological | 2006 |
Sexual side effects of serotonergic antidepressants: mediated by inhibition of serotonin on central dopamine release?
Topics: Animals; Antidepressive Agents; Aza Compounds; Brain; Bridged Bicyclo Compounds, Heterocyclic; Bupropion; Buspirone; Cyclohexanols; Disease Models, Animal; Dopamine; Female; Humans; Indoles; Male; Norepinephrine; Paroxetine; Pyridines; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Serotonin; Sexual Behavior, Animal; Sexual Dysfunction, Physiological; Synaptic Transmission; Venlafaxine Hydrochloride | 2014 |
Empirically Supported Use of Psychiatric Medications in Adolescents and Adults with IBD.
Topics: Adolescent; Adult; Affect; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Anxiety; Bupropion; Buspirone; Depression; Gastrointestinal Tract; Humans; Immunity; Inflammatory Bowel Diseases; Mianserin; Mirtazapine; Pain; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Young Adult | 2016 |
6 trial(s) available for bupropion and buspirone
| Article | Year |
|---|---|
Medication augmentation after the failure of SSRIs for depression.
Topics: Adult; Bupropion; Buspirone; Citalopram; Delayed-Action Preparations; Depressive Disorder, Major; Dopamine Uptake Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Logistic Models; Male; Remission Induction; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Treatment Failure | 2006 |
Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report.
Topics: Adult; Ambulatory Care; Antidepressive Agents; Bupropion; Buspirone; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cross-Over Studies; Cyclohexanols; Decision Trees; Delayed-Action Preparations; Depressive Disorder, Major; Female; Humans; Male; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Treatment Outcome; Venlafaxine Hydrochloride | 2007 |
What predicts attrition in second step medication treatments for depression?: a STAR*D Report.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Bupropion; Buspirone; Citalopram; Data Interpretation, Statistical; Depressive Disorder, Major; Drug Therapy, Combination; Female; Forecasting; Humans; Male; Middle Aged; Outpatients; Patient Dropouts; Prospective Studies; Psychiatric Status Rating Scales; Quality of Life; Serotonin Receptor Agonists; Socioeconomic Factors; Young Adult | 2009 |
Pharmacogenetics studies in STAR*D: strengths, limitations, and results.
Topics: Adult; Biomarkers; Bupropion; Buspirone; Citalopram; Cognitive Behavioral Therapy; Comorbidity; Cyclohexanols; Depressive Disorder, Major; Dopamine Uptake Inhibitors; Humans; Pharmacogenetics; Phenotype; Polymorphism, Single Nucleotide; Receptor, Serotonin, 5-HT2A; Receptors, Kainic Acid; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Serotonin Receptor Agonists; Sertraline; Treatment Failure; Treatment Outcome; Venlafaxine Hydrochloride | 2009 |
Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Bupropion; Buspirone; Citalopram; Delayed-Action Preparations; Depressive Disorder, Major; Humans; Middle Aged; Quality of Life; Treatment Outcome | 2012 |
Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Bupropion; Buspirone; Citalopram; Cyclohexanols; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Female; Humans; Likelihood Functions; Male; Middle Aged; Personality Inventory; Psychometrics; Quality of Life; Sertraline; United States; Venlafaxine Hydrochloride; Young Adult | 2012 |
22 other study(ies) available for bupropion and buspirone
| Article | Year |
|---|---|
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
Topics: Blood-Brain Barrier; Lipid Bilayers; Micelles; Permeability; Pharmaceutical Preparations; Structure-Activity Relationship; Surface Properties | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
Topics: Absorption; Albumins; Animals; Brain; Brain Chemistry; Cell Membrane; Chromatography, High Pressure Liquid; Drug Evaluation, Preclinical; In Vitro Techniques; Lipids; Male; Microdialysis; Pharmaceutical Preparations; Protein Binding; Rats; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Swine; Tissue Distribution | 2011 |
Species independence in brain tissue binding using brain homogenates.
Topics: Animals; Brain; Dogs; Guinea Pigs; Humans; Macaca fascicularis; Mice; Rats; Species Specificity | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Bupropion-induced acute dystonia.
Topics: Acute Disease; Adult; Bupropion; Buspirone; Depression; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Dystonia; Humans; Male; Serotonin Receptor Agonists | 2002 |
Marked suppression of gastric ulcerogenesis and intestinal responses to stress by a novel class of drugs.
Topics: Analysis of Variance; Animals; Bupropion; Buspirone; Colon; Corticotropin-Releasing Hormone; Diazepam; Dose-Response Relationship, Drug; Fluoxetine; Gastric Mucosa; Male; Mucins; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Corticotropin-Releasing Hormone; Stomach Ulcer | 2002 |
Depression--augmentation or switch after initial SSRI treatment.
Topics: Bupropion; Buspirone; Citalopram; Delayed-Action Preparations; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Placebo Effect; Remission Induction; Research Design; Selective Serotonin Reuptake Inhibitors | 2006 |
The combination of buspirone and bupropion in the treatment of depression.
Topics: Bupropion; Buspirone; Depressive Disorder, Major; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Female; Humans; Middle Aged; Serotonin Receptor Agonists | 2007 |
Augmentation strategies to increase antidepressant efficacy.
Topics: Algorithms; Bupropion; Buspirone; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Drug Synergism; Humans; Remission Induction; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Sertraline | 2007 |
Low-dose buspirone, melatonin and low-dose bupropion added to mood stabilizers for severe treatment-resistant bipolar depression.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Bupropion; Buspirone; Drug Therapy, Combination; Female; Humans; Melatonin | 2009 |
Does the presence of accompanying symptom clusters differentiate the comparative effectiveness of second-line medication strategies for treating depression?
Topics: Adult; Bias; Bupropion; Buspirone; Cluster Analysis; Cyclohexanols; Depressive Disorder; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Sertraline; Treatment Failure; Treatment Outcome; Venlafaxine Hydrochloride | 2011 |
Do suicidal thoughts or behaviors recur during a second antidepressant treatment trial?
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Buspirone; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Substitution; Drug Therapy, Combination; Female; Humans; Intention; Male; Middle Aged; Multicenter Studies as Topic; Odds Ratio; Personality Inventory; Primary Health Care; Randomized Controlled Trials as Topic; Recurrence; Retrospective Studies; Risk Factors; Sertraline; Suicidal Ideation; Suicide, Attempted; Thinking; Venlafaxine Hydrochloride | 2012 |